Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients

Circulating tumour DNA (ctDNA) can be used to identify gene alterations. The purpose of this study was to determine whether the detection of ctDNA, based on the identification of BRAF and NRAS mutations before systemic treatment initiation, was associated with the prognosis of metastatic melanoma. I...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancers (Basel)
Main Authors: Herbreteau, Guillaume, Vallée, Audrey, Knol, Anne-Chantal, Théoleyre, Sandrine, Quéreux, Gaelle, Frénard, Cécile, Varey, Emilie, Hofman, Paul, Khammari, Amir, Dréno, Brigitte, Denis, Marc G.
Format: Artigo
Sprog:Inglês
Udgivet: MDPI 2020
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7409003/
https://ncbi.nlm.nih.gov/pubmed/32664549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12071871
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker